DRL 17822

Drug Profile

DRL 17822

Alternative Names: CZ0L3; DRL-17822

Latest Information Update: 17 Dec 2015

Price : $50

At a glance

  • Originator Dr Reddys Laboratories
  • Developer Centre for Human Drug Research; Dr Reddys Laboratories
  • Class Antihyperlipidaemics; Small molecules
  • Mechanism of Action Cholesterol ester transfer protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Hyperlipoproteinaemia type II
  • Phase I Atherosclerosis; Dyslipidaemias

Most Recent Events

  • 30 Jun 2012 Dr Reddy's Laboratories completes a phase II trial in Hyperlipoproteinaemia type II in Italy, Poland and Ukraine (NCT01388816)
  • 09 Mar 2012 Dr Reddy's Laboratories completes enrolment in its phase II trial for Hyperlipoproteinaemia type II in Italy, Poland and Ukraine (NCT01388816)
  • 02 Sep 2011 Phase-II clinical trials in Hyperlipoproteinaemia type II in Ukraine (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top